Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Thrombospondin 1
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Thrombospondin 1

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

An extracellular matrix glycoprotein from platelets and a variety of normal and transformed cells of both mesenchymal and epithelial origin.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (883 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

An extracellular matrix glycoprotein from platelets and a variety of normal and transformed cells of both mesenchymal and epithelial origin. Thrombospondin-1 is believed to play a role in cell migration and proliferation, during embryogenesis and wound repair. Also, it has been studied for its use as a potential regulator of tumor growth and metastasis.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: TSP-1.

Where it fits in the MeSH classification

Broader topics
Thrombospondins

Research landscape

PubMed indexes 2,447 records tagged with the MeSH heading “Thrombospondin 1” (counts retrieved 2026-10-31). 528 of them (21.6%) were published from 2020 onward, and the busiest period so far is 2000-2009 with 936 records.

Reviews account for 165 records (6.7%) and meta-analyses for 4. Randomized controlled trials number 12 (0.5%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 99 records; 2000-2009: 936 records; 2010-2019: 884 records; 2020 onward: 528 records99through 19999362000-20098842010-20195282020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 199999
2000-2009936
2010-2019884
2020 onward528
Share of records by publication typeReviews: 6.7 percent; Meta-analyses: 0.2 percent; Randomized controlled trials: 0.5 percentReviews6.7% (165)Meta-analyses0.2% (4)Randomized controlled trials0.5% (12)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 2,447 PubMed records
TypeRecordsShare
Reviews1656.7%
Meta-analyses40.2%
Randomized controlled trials120.5%

Method: PubMed query "Thrombospondin 1"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma
Xiao M, Zhang J, Chen W, Chen W
2018Research article
Design not recorded in structured metadata
217cc by
PMID 29986759 · DOI · PMC6038304
Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer
Shen J, Cao B, Wang Y, Ma C, Zeng Z, Liu L, et al.
2018Research article
Design not recorded in structured metadata
194cc by
PMID 30055645 · DOI · PMC6064138
Deciphering the complex role of thrombospondin-1 in glioblastoma development
Daubon T, Léon C, Clarke K, Andrique L, Salabert L, Darbo E, et al.
2019Research article
Design not recorded in structured metadata
183cc by
PMID 30850588 · DOI · PMC6408502
Thrombospondin 1 and 2 regulate mesenchymal progenitor cell fate and matrix organization
Hunter MK, Korlakunta S, Vishlaghi N, Mittal M, Cragg K, Juan C, et al.
2026Research article
Design not recorded in structured metadata
6cc by
PMID 41554713 · DOI · PMC12816047

M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma [1]

Research article Xiao M, Zhang J, Chen W, Chen W · · 2018 · cited 217 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundTreatment strategies targeting tumor-associated macrophages (TAMs) have been proposed in cancer areas.
Closing excerpt
Therefore, target management of M1-like TAMs polarized by exosomes shows great potential as a therapeutic target for the control of cancerous migration in OSCC.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (231 words)

BackgroundTreatment strategies targeting tumor-associated macrophages (TAMs) have been proposed in cancer areas. The functional alterations of macrophages in the microenvironment during the tumorigenesis of human epithelial cancer remain poorly understood. Here, we explored phenotypic alteration of macrophages during the development of oral squamous cell carcinoma (OSCC).MethodsConditioned media (CM) and exosome supernatants were harvested from normal oral epithelium, oral leukoplakia cells and OSCC cells. We measured phenotypic alteration of macrophages using flow cytometry, luminex assays, and quantitative real-time PCR assay. Intracellular signaling pathway analysis, mass spectrometry proteomics, western blotting, enzyme-linked immunosorbent assay, immunohistochemical staining, and bioinformatics analysis were performed to uncover the underlying mechanisms.ResultsTHP-1-derived and PBMCs derived macrophages exhibited an M1-like phenotype but not M2-like phenotype, when treated with CM from OSCC cells but not with the CM from normal epithelium or leukoplakia cells. Further investigations revealed that macrophages were activated by taking up exosomes released from OSCC cells through p38, Akt, and SAPK/JNK signaling at the early phase. We further provided evidences that THBS1 derived from OSCC exosomes participated in the polarization of macrophages to an M1-like phenotype. Reciprocally, CM from exosomes induced M1-like TAMs and significantly promoted migration of OSCC cells.ConclusionsWe proposed a novel paracrine loop between cancer cells and macrophages based on exosomes from OSCC. Therefore, target management of M1-like TAMs polarized by exosomes shows great potential as a therapeutic target for the control of cancerous migration in OSCC.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 29986759 · DOI · PMC6038304

Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer [2]

Research article Shen J, Cao B, Wang Y, Ma C, Zeng Z, Liu L, et al. · · 2018 · cited 194 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundFocal adhesion plays an essential role in tumour invasiveness and metastasis.
Closing excerpt
ConclusionOur results unveil a new signal axis, YAP/THBS1/FAK, in the modulation of cell adhesion and invasiveness, and provides new insights into the crosstalk between Hippo signalling and focal adhesion.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (331 words)

BackgroundFocal adhesion plays an essential role in tumour invasiveness and metastasis. Hippo component YAP has been widely reported to be involved in many aspects of tumour biology. However, its role in focal adhesion regulation in breast cancer remains unexplored.MethodsTissue microarray was used to evaluate YAP expression in clinical breast cancer specimens by immunohistochemical staining. Cell migration and invasion abilities were measured by Transwell assay. A cell adhesion assay was used to measure the ability of cell adhesion to gelatin. The focal adhesion was visualized through immunofluorescence. Phosphorylated FAK and other proteins were detected by Western blot analysis. Gene expression profiling was used to screen differently expressed genes, and gene ontology enrichment was performed using DAVID software. The gene mRNA levels were measured by quantitative real-time PCR. The activity of the THBS1-promoter was evaluated by dual luciferase assay. Chromatin immunoprecipitation (ChIP) was used to verify whether YAP could bind to the THBS1-promoter region. The prediction of potential protein-interaction was performed with the String program. The ChIP sequence data of TEAD was obtained from the ENCODE database and analysed via the ChIP-seek tool. The gene expression dataset (GSE30480) of purified tumour cells from primary breast tumour tissues and metastatic lymph nodes was used in the gene set enrichment analysis. Prognostic analysis of the TCGA dataset was performed by the SurvExpress program. Gene expression correlation of the TCGA dataset was analysed via R2: Genomics Analysis and Visualization Platform.ResultsOur study provides evidence that YAP acts as a promoter of focal adhesion and tumour invasiveness via regulating FAK phosphorylation in breast cancer. Further experiments reveal that YAP could induce FAK phosphorylation through a TEAD-dependent manner. Using gene expression profiling and bioinformatics analysis, we identify the FAK upstream gene, thrombospondin 1, as a direct transcriptional target of YAP-TEAD. Silencing THBS1 could reverse the YAP-induced FAK activation and focal adhesion.ConclusionOur results unveil a new signal axis, YAP/THBS1/FAK, in the modulation of cell adhesion and invasiveness, and provides new insights into the crosstalk between Hippo signalling and focal adhesion.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30055645 · DOI · PMC6064138

Deciphering the complex role of thrombospondin-1 in glioblastoma development [3]

Research article Daubon T, Léon C, Clarke K, Andrique L, Salabert L, Darbo E, et al. · · 2019 · cited 183 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
We undertook a systematic study focused on the matricellular protein Thrombospondin-1 (THBS1) to uncover molecular mechanisms underlying the role of THBS1 in glioblastoma (GBM) development.
Closing excerpt
Furthermore, tumour cell-bound CD47 is implicated in this process.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (150 words)

We undertook a systematic study focused on the matricellular protein Thrombospondin-1 (THBS1) to uncover molecular mechanisms underlying the role of THBS1 in glioblastoma (GBM) development. THBS1 was found to be increased with glioma grades. Mechanistically, we show that the TGFβ canonical pathway transcriptionally regulates THBS1, through SMAD3 binding to the THBS1 gene promoter. THBS1 silencing inhibits tumour cell invasion and growth, alone and in combination with anti-angiogenic therapy. Specific inhibition of the THBS1/CD47 interaction using an antagonist peptide decreases cell invasion. This is confirmed by CD47 knock-down experiments. RNA sequencing of patient-derived xenograft tissue from laser capture micro-dissected peripheral and central tumour areas demonstrates that THBS1 is one of the gene with the highest connectivity at the tumour borders. All in all, these data show that TGFβ1 induces THBS1 expression via Smad3 which contributes to the invasive behaviour during GBM expansion. Furthermore, tumour cell-bound CD47 is implicated in this process.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30850588 · DOI · PMC6408502

Thrombospondin 1 and 2 regulate mesenchymal progenitor cell fate and matrix organization [4]

Research article Hunter MK, Korlakunta S, Vishlaghi N, Mittal M, Cragg K, Juan C, et al. · · 2026 · cited 6 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Thrombospondin 1 and 2 (TSP1 and TSP2) are critical regulators of extracellular matrix (ECM) interactions, influencing cell differentiation and tissue repair.
Closing excerpt
These findings highlight the crucial roles of TSP1 and TSP2 in musculoskeletal injury repair as well as HO formation and progression, supporting the potential to therapeutically target TSP1 and TSP2 to prevent HO.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (171 words)

Thrombospondin 1 and 2 (TSP1 and TSP2) are critical regulators of extracellular matrix (ECM) interactions, influencing cell differentiation and tissue repair. Recent discoveries from our laboratory and others highlight the importance of altered ECM alignment in influencing aberrant mesenchymal progenitor cell (MPC) differentiation and subsequent ectopic bone formation in trauma-induced heterotopic ossification (HO). However, the key regulators of this MPC to ECM interaction have yet to be elucidated. This study uncovers the role of matricellular TSP1 and TSP2 in MPC/ECM interaction as well as HO formation and progression. Using single-cell RNA sequencing, spatial transcriptomics, and in vivo models, we found that TSP1 is upregulated in tissue remodeling macrophages and MPCs at the injury site, while TSP2 is restricted to MPCs surrounding the HO anlagen. TSP1/2 double knockout (DKO) mice exhibited significantly reduced HO volume and disrupted ECM alignment. These findings highlight the crucial roles of TSP1 and TSP2 in musculoskeletal injury repair as well as HO formation and progression, supporting the potential to therapeutically target TSP1 and TSP2 to prevent HO.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41554713 · DOI · PMC12816047

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology [5]
    Murphy-Ullrich JE, Poczatek M · Cytokine Growth Factor Rev · 2000 · cited 449 times (Europe PMC)
  • Research article Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2 [6]
    Lawler PR, Lawler J · Cold Spring Harb Perspect Med · 2012 · cited 411 times (Europe PMC)
  • Research article Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth [7]
    Lawler J · J Cell Mol Med · 2002 · cited 410 times (Europe PMC)
  • Research article Thrombospondins as matricellular modulators of cell function [8]
    Bornstein P · J Clin Invest · 2001 · cited 363 times (Europe PMC)
  • Research article The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? [9]
    Murphy-Ullrich JE · J Clin Invest · 2001 · cited 348 times (Europe PMC)
  • Research article The functions of thrombospondin-1 and-2 [10]
    Lawler J · Curr Opin Cell Biol · 2000 · cited 336 times (Europe PMC)

References

  1. Xiao M, Zhang J, Chen W, Chen W. M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma. . 2018. PMID 29986759 · DOI · PMC6038304
  2. Shen J, Cao B, Wang Y, Ma C, Zeng Z, Liu L, et al.. Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer. . 2018. PMID 30055645 · DOI · PMC6064138
  3. Daubon T, Léon C, Clarke K, Andrique L, Salabert L, Darbo E, et al.. Deciphering the complex role of thrombospondin-1 in glioblastoma development. . 2019. PMID 30850588 · DOI · PMC6408502
  4. Hunter MK, Korlakunta S, Vishlaghi N, Mittal M, Cragg K, Juan C, et al.. Thrombospondin 1 and 2 regulate mesenchymal progenitor cell fate and matrix organization. . 2026. PMID 41554713 · DOI · PMC12816047
  5. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000. PMID 10708953 · DOI
  6. Lawler PR, Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med. 2012. PMID 22553494 · DOI · PMC3331684
  7. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med. 2002. PMID 12003665 · DOI · PMC6740251
  8. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest. 2001. PMID 11306593 · DOI · PMC199563
  9. Murphy-Ullrich JE. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state?. J Clin Invest. 2001. PMID 11285293 · DOI · PMC199582
  10. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol. 2000. PMID 10978901 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • beta 2-MicroglobulinDrugs and Chemicals
  • CadherinsDrugs and Chemicals
  • Carcinoembryonic AntigenDrugs and Chemicals
  • CD40 LigandDrugs and Chemicals
  • Cell Adhesion Molecule-1Drugs and Chemicals
  • Cell Adhesion MoleculesDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

2,447
PubMed records on this heading
22%
published since 2020
165
review articles
12
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • beta 2-MicroglobulinDrugs and Chemicals
  • CadherinsDrugs and Chemicals
  • Carcinoembryonic AntigenDrugs and Chemicals
  • CD40 LigandDrugs and Chemicals
  • Cell Adhesion Molecule-1Drugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support